Helicobacter pylori (Hp) infection
Conditions
Interventions
Vonolassen-clarithromycin group:Vonorasen-clarithromycin dual therapy: vonorrasheng (20mg twice a day after meals) and clarithromycin (0.5g twice a day after meals) for 14 days
Vonorasen-levofloxacin group:Vonoraxen + levofloxacin: Vonoraxen (20 mg twice a day after meals) levofloxacin (0.5 g once a day after meals) for 14 days
Vonorasan + metronidazole group:Vornorxen-metronidazole dual therapy: vonorasen (20 mg twice a day after meals), metronidazole (0.4 g qid after meals and at bedtime
If the adverse reaction is obvious, change to TID), and the course of treatment is 14 days
Vonorasen-tetracycline group:Vonorrasang-tetracycline dual therapy: vonorrasen (20 mg twice a day after meals), tetracycline (0.5 g qid after meals and at bedtime
Vonorazen-furazolidone group:Vonorazen-furazolidone dual therapy: vonorrasen (20 mg twice a day after meals), furazolidone (0.1 g tid after meals
If the adverse reaction is obvious, change to bid), the course of treatment is 14 days
Vonorasen-minocycline group:Vonorasen-minocycline dual therapy: vonorrasan (20 mg twice a day after meals), minocycline (0.1 g twice a day after meals), a course of treatment for 14 days
Vonorasen-cefuroxime group:Vonorazen-cefuroxime dual therapy: vonorrasan (20mg twice a day after meals), cefuroxime (0.5g twice a day after meals), a course of treatment for 14 days
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with current Helicobacter pylori infection 2. Have not received Helicobacter pylori eradication therapy before 3. Age 18-75 years old 4. Voluntary participation and ability to cooperate with this study
Exclusion criteria
Exclusion criteria: 1. Have taken drugs that may affect the results of the study, such as PPI, P-CAB, bismuth, antibiotics, etc., within 4 weeks before enrollment 2. Patients with malignant tumors of the digestive tract 3. Gastrinoma patients 4. Patients after gastrointestinal or esophageal surgery 5. Patients with serious underlying diseases 6. Patients who are allergic to the drugs used in this study or are taking drugs that may have adverse interactions with them 7. Pregnant or lactating women 8. Patients with alcoholism or alcohol dependence 9. Other conditions that may generate risk events
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactSong Zhiqiang
Department of Gastroenterology, Peking University Third Hospital
Outcome results
None listed